Argenx SE shares are experiencing downward pressure, driven by widespread volatility across the biotech sector and increased scrutiny of its product pipeline. Despite the challenges, some analysts view the current valuation as a potential buying opportunity.

Argenx Shares Under Pressure Amid Biotech Volatility.
|1 min read
ARGXBiotechStock VolatilityPipeline ScrutinyHealthcare Sector

